Key result
In low-risk patients with preserved left ventricular ejection fraction, continuation of β-blocker therapy after CABG surgery was not associated with a reduction in cardiovascular events (HR 0.97).
Why the study?
Does beta-blocker therapy reduce cardiovascular events or angina in stable, low-risk patients with preserved LVEF after CABG surgery?
Observational (n=2,233)
Yes
Does beta-blocker therapy reduce cardiovascular events or angina in stable, low-risk patients with preserved LVEF after CABG surgery?
Hazard Ratio: 0.97 (95% CI 0.74–1.27)
Routine continuation of beta-blocker therapy after CABG in stable, low-risk patients with preserved LVEF is not associated with improved cardiovascular outcomes or reduced angina.
May not support routine β-blocker continuation post-CABG in low-risk preserved-LVEF patients; leaves open confirmation by RCTs.
PURPOSE: To evaluate whether β-blockers were associated with a reduction in cardiovascular events or angina after Coronary Artery Bypass Graft (CABG) surgery, in otherwise stable low-risk patients during a mid-term follow-up. METHODS: We performed a post-hoc analysis of the IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of angiotensin coNverting Enzyme) trial, which tested the effect of Quinapril in 2553 hemodynamically stable patients with left ventricular ejection fraction (LVEF) >40 %, after scheduled CABG. The association between β-blocker therapy and the incidence of cardiovascular events (death, cardiac arrest, myocardial infarction, revascularizations, angina requiring hospitalization, stroke or hospitalization for heart failure) or angina that was documented to be due to underlying ischemia was tested with Cox regression and propensity adjusted analyses. RESULTS: In total, 1709 patients (76.5 %) were using a β-blocker. Patients had excellent control of risk factors; with mean systolic blood pressure being 121 ± 14 mmHg, mean LDL cholesterol of 2.8 mmol/l, 59% of patients received statins and 92% of patients received antiplatelet therapy. During a median follow-up of 33 months, β-blocker therapy was not associated with a reduction in cardiovascular events (hazard ratio 0.97; 95 % confidence interval 0.74-1.27), documented angina (hazard ratio 0.85; 95 % confidence interval 0.61-1.19) or any of the individual components of the combined endpoint. There were no relevant interactions for demographics, comorbidities or surgical characteristics. Propensity matched and time-dependent analyses revealed similar results. CONCLUSIONS: β-blocker therapy after CABG is not associated with reductions in angina or cardiovascular events in low-risk patients with preserved LVEF, and may not be systematically indicated in such patients.
No takes yet. Share an insight, caveat, or question.
Booij et al. (2015) conducted an observational in Coronary Artery Disease post-CABG (n=2,233). β-blocker therapy vs. No β-blocker therapy was evaluated on Composite of cardiovascular death, resuscitated cardiac arrest, nonfatal MI, coronary revascularization, unstable angina requiring hospitalization, documented angina not requiring hospitalization, congestive heart failure requiring hospitalization, and stroke (HR 0.97, 95% CI 0.74-1.27). In low-risk patients with preserved left ventricular ejection fraction, continuation of β-blocker therapy after CABG surgery was not associated with a reduction in cardiovascular events (HR 0.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: